Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 11/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | RORB | Q92753 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257442 | 1.00 | SLC10A1 (0.39) | SLC10A1GRM4RORCRORBXDH | |
| SCHEMBL17700879 | 0.88 | GRM4 (0.42) | SLC10A1GRM4F11 | |
| SCHEMBL17700846 | 0.88 | GRM4 (0.42) | SLC10A1GRM4XDHF11 | |
| SCHEMBL16257191 | 0.88 | GRM4 (0.42) | SLC10A1GRM4F11 | |
| SCHEMBL18408070 | 0.86 | GRM4 (0.38) | SLC10A1GRM4XDHKDM1A | |
| SCHEMBL22579501 | 0.82 | GRM4 (0.42) | SLC10A1GRM4 | |
| SCHEMBL16257319 | 0.81 | GRM4 (0.41) | SLC10A1GRM4 | |
| SCHEMBL16257389 | 0.81 | GRM4 (0.41) | SLC10A1GRM4 | |
| SCHEMBL17700822 | 0.80 | SLC10A1 (0.39) | SLC10A1GRM4RORCF11 | |
| SCHEMBL21727644 | 0.80 | GRM4 (0.40) | SLC10A1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305116-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305116-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | HAVCR2, HCCS, IRF3 | SLC10A1 52/4885GRM4 1761/4885RORC 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.